Antimicrobial Use in the Treatment of Calf Diarrhea

Peter D. Constable

Calves with diarrhea often have small intestinal overgrowth with Escherichia coli bacteria, regardless of the inciting cause for the diarrhea, and 30% of systemically ill calves with diarrhea have bacteremia, predominantly because of E. coli. Antimicrobial treatment of diarrheic calves should therefore be focused against E. coli in the small intestine and blood, the 2 sites of infection. Fecal bacterial culture and antimicrobial susceptibility testing is not recommended in calves with diarrhea because fecal bacterial populations do not accurately reflect small intestinal or blood bacterial populations and because the break points for susceptibility test results have not been validated. Antimicrobial efficacy is therefore best evaluated by the clinical response of a number of calves to treatment, with calves randomly assigned to treatment groups. Amoxicillin, clortetracycline, neomycin, oxytetracycline, streptomycin, sulfachloropyridazine, sulfamethazine, and tetracycline administered PO are currently labeled in the United States for the treatment of calf diarrhea. On the basis of published evidence for the oral administration of these antimicrobial agents, only amoxicillin can be recommended for the treatment of diarrhea. Dosage recommendations are amoxicillin trihydrate (10 mg/kg PO q12h) or amoxicillin trihydrate–clavulanate potassium (12.5 mg combined drug/kg PO q12h) for at least 3 days; the latter constitutes extra-label drug use. Parenteral administration of broad-spectrum $\beta$-lactam antimicrobials—ceftiofur (2.2 mg/kg IM or SC q12h) and amoxicillin or ampicillin (10 mg/kg IM q12h)—or potentiated sulfonamides (25 mg/kg IV or IM q24h) is recommended for treating calves with diarrhea and systemic illness; both constitute extra-label drug use. In calves with diarrhea and no systemic illness (normal appetite for milk, no fever), it is recommended that the health of the calf be monitored and that oral or parenteral antimicrobials not be administered.

Key words: Antimicrobial; Escherichia coli; Salmonella; septicemia; susceptibility.
In calves with experimentally induced enterotoxigenic *E. coli* diarrhea, colonization of the small intestine by *E. coli* has been associated with impaired glucose and lactose absorption, decreased serum glucose concentration, and possibly increased susceptibility to cryptosporidial infection.13

Calves with diarrhea often have increased coliform bacterial numbers in the small intestine, regardless of etiology (Fig 1).3,8,14 and this colonization is associated with altered small intestinal function, morphologic damage, and increased susceptibility to bacteremia. It therefore follows that administration of antimicrobial agents that decrease small intestinal coliform bacterial numbers in calves with diarrhea might prevent the development of bacteremia, decrease mortality, and decrease morphologic damage to the small intestine, thereby facilitating digestion and absorption and increasing growth rate.

**Incidence of Bacteremia in Calves with Diarrhea**

Calves with diarrhea are more likely to have failure or partial failure of passive transfer, and this group of calves, in turn, is more likely to be bacteremic. This is an additional reason that antimicrobial agents might be indicated in the treatment of calf diarrhea. Smith reported in 19622 that colostrum-deprived calves that subsequently developed diarrhea were frequently bacteremic (14/17 = 82%), whereas bacteremia occurred much less frequently in colostrum-fed calves that developed diarrhea (0/26 = 0%). Similar results have been observed in 2 recent North American studies.15,16 These studies identified bacteremia in calves with a median age of 8 days15 or a mean age of 9 days16; these results were at odds with current dogma that calf septicemia and bacteremia occur most frequently in the 1st few days of life.

Fecteau et al15 examined 169 dairy calves <20 days old with severe diarrhea or depression on a large California calf-rearing facility; 129 of 169 (76%) of the calves had failure of passive transfer of colostral immunoglobulin, and 47 of 169 (28%) of the affected calves were bacteremic, predominantly with *E. coli*. Bacteremia was detected in a significantly (*P = .0010*) greater proportion of calves with failure of passive transfer (44/129 = 34%) than in calves with adequate passive transfer (3/40 = 8%); however, the number of calves with severe diarrhea and bacteremia was not specifically stated.

Lofstedt and her colleagues examined 252 calves <28 days old with diarrhea on Prince Edward Island, Canada.16 The feces of diarrheic calves were examined for enteric pathogens and were positive for coronavirus (39%), enterotoxigenic *E. coli* (38%), cryptosporidia (33%), and rotavirus (12%). Forty-one percent (103/252) of the calves had failure of passive transfer of colostral immunoglobulin, and 31% (78/252) of the calves were bacteremic, predominantly with *E. coli*. Bacteremia was detected in a significantly (*P < .0001*) greater proportion of calves with failure of passive transfer (47/103 = 46%) than in calves with adequate passive transfer (21/116 = 18%) and calves ≤5 days old.

The results of these 2 studies indicate that veterinarians should assume that, on average, 30% of severely ill calves with diarrhea are bacteremic, that the risk of bacteremia is higher in calves with failure of passive transfer than in calves with adequate passive transfer, and that the risk of bacteremia is higher in calves ≤5 days old. The frequency of bacteremia is sufficiently high that treatment of calves with diarrhea that are severely ill (as manifested by reduced suckle reflex, >6% dehydration, weakness, inability to stand, or clinical depression) should include routine treatment against bacteremia, with emphasis on treating potential *E. coli* bacteremia. Veterinarians should also assume that 8%15 to 18%16 of diarrheic calves with adequate passive transfer and systemic illness are bacteremic. In the author’s opinion, the prevalence of bacteremia is sufficiently high in systemically ill calves that effective antimicrobial treatment for potential bacteremia should be routinely instituted, regardless of passive transfer status and treatment cost. Withholding an effective treatment for a life-threatening condition, such as bacteremia in calves with diarrhea, cannot be condoned on animal welfare grounds.

**Safety and Efficacy of Antimicrobials in Treating Calf Diarrhea**

The appropriate use of antimicrobial agents to treat calf diarrhea would be facilitated by publication of controlled, randomized treatment studies in peer-reviewed journals. Unfortunately, the majority of the valuable information...
generated by pharmaceutical companies to support their label claim of treating calf diarrhea has not been published and is therefore unavailable for independent evaluation.

On the basis of the previous discussion, the 2 primary reasons for administering antimicrobial agents to calves with diarrhea are (1) to decrease the number of *E. coli* bacteria in the small intestine and (2) to treat potential *E. coli* bacteremia. It therefore follows that when antimicrobial agents are administered to calves with diarrhea, the antimicrobial should be safe and effective against *E. coli* in both the small intestine and blood, which should be regarded as the 2 sites of infection.

**Antimicrobial Safety**

A number of antimicrobial agents produce deleterious effects on small intestinal function and morphology when administered PO to healthy milk-fed dairy calves. The addition to milk replacer powder of potassium penicillin (11 mg/kg of milk replacer) and procaine penicillin (2–60 mg/kg of milk replacer) increased the incidence and duration of diarrhea and decreased growth rate compared with untreated controls in a total of 36 milk-fed calves. Administration of neomycin sulfate (300 mg PO q24h for the 1st 4 days of life) tended (*P* = .060) to increase the proportion of calves developing diarrhea (99/233 = 43%) compared with the proportion in an untreated control group (58/174 = 33%). Administration of neomycin sulfate (25 mg/kg PO q6h, *n* = 10), chloramphenicol (50 mg/kg PO q12h, *n* = 6), ampicillin trihydrate (12 mg/kg PO q8h, *n* = 6), or tetracycline hydrochloride (11 mg/kg PO q12h, *n* = 6) for 5 days increased the occurrence of diarrhea and decreased glucose absorption through unknown mechanisms compared with untreated controls (*n* = 6), whereas 2 other studies found that tetracycline hydrochloride (40 mg PO q12h; 11 mg/kg PO q12h) did not induce diarrhea or alter glucose absorption. In a separate study, administration of chloramphenicol (50 mg/kg PO q12h for 3 days) to healthy neonatal calves decreased jejunal villous length and α-xylene absorption and increased breath H2 excretion, indicating small intestinal malabsorption, which was attributed to a chloramphenicol-induced decrease in intestinal epithelial mitochondria protein synthesis. Other investigators reported that administration of chloramphenicol (50 mg/kg PO q12h) induced diarrhea in 7 of 8 calves within 5 days, although this study did not contain a control group. Finally, administration of chloramphenicol (55 mg/kg PO q12h for 5 days) did not induce diarrhea in 7 calves, but delayed glucose absorption. The effects of prolonged oral chloramphenicol administration in calves raises the question as to whether other antimicrobial agents administered PO induce diarrhea or alter small intestinal function or morphology; such a deleterious effect is less likely to occur after administration of antimicrobial agents with high oral bioavailability.

**Antimicrobial Susceptibility**

The most important determinant of antimicrobial efficacy in calf diarrhea is obtaining an effective antimicrobial concentration against bacteria at the sites of infection (small intestine and blood). The results of fecal antimicrobial susceptibility testing have traditionally been used to guide treatment decisions; however, susceptibility testing in calf diarrhea probably has clinical relevance only when applied to fecal isolates of enterotoxigenic strains of *E. coli* or pathogenic *Salmonella* spp and blood culture isolates from calves with bacteremia. Validation of susceptibility testing as being predictive of treatment outcome for calves with diarrhea is currently lacking.

**Antimicrobial Susceptibility of Fecal E. coli Isolates.**

The ability of fecal bacterial culture and antimicrobial susceptibility testing by the Kirby Bauer technique to guide treatment in calf diarrhea is questionable when applied to fecal *E. coli* isolates that have not been identified as enterotoxigenic, although 2 reports concluded that a “good correlation” existed between in vitro antimicrobial susceptibility of fecal *E. coli* isolates and clinical response to antimicrobial treatment. In contrast, 3 other studies reported no correlation between in vitro antimicrobial susceptibility of fecal *E. coli* and *Salmonella* spp isolates and clinical response to antimicrobial treatment, although these studies did not differentiate enterotoxigenic and nonenterotoxigenic strains of *E. coli*. The only study to statistically test the predictive ability of fecal antimicrobial susceptibility results found that the rectal swab was an inaccurate method of predicting clinical outcome. There do not appear to be any data demonstrating that fecal bacterial flora is representative of small intestinal bacterial flora, which is the physiologically important site of infection in calf diarrhea. Finally, and most importantly, the predominant strain of *E. coli* in the feces of a scouring calf can change several times during the diarrhea episode, and 9 of 20 (45%) calves with diarrhea had different strains of *E. coli* isolated from the upper and lower small intestine, indicating that fecal *E. coli* strains are not always representative of small intestinal *E. coli* strains.

An additional bias present in most antimicrobial susceptibility studies conducted on fecal *E. coli* isolates is that data are frequently obtained from dead calves, which are likely to be treatment failures. The time since death is also likely to be an important determinant of the value of fecal culture because “such a rapid proliferation of bacteria occurs in the alimentary tract after death that the results of examinations made on dead calves received at the laboratory can have little significance.” Calves that die from diarrhea are likely to have received multiple antimicrobial treatments, and preferential growth of antimicrobial-resistant *E. coli* strains starts within 3 hours of antimicrobial administration. A 3rd concern with fecal susceptibility testing is that the Kirby Bauer break points (minimum inhibitory concentration [MIC]) are not based on typical antimicrobial concentrations in the small intestine and blood of calves. What is urgently needed are studies documenting the antimicrobial susceptibility of *E. coli* isolates from the small intestine of untreated calves on the basis of achievable drug concentrations and dosage regimens. Until these data are available, it appears that antimicrobial efficacy is best evaluated by the clinical response of a number of calves to treatment, with calves randomly assigned to treatment groups, rather than the results of in vitro antimicrobial susceptibility testing performed on fecal *E. coli* isolates.
**Antimicrobial Susceptibility of Blood E. coli Isolates.**
The Kirby Bauer technique for the antimicrobial susceptibility test has more clinical relevance for predicting the clinical response to antimicrobial treatment when applied to blood isolates than fecal isolates. This is because the Kirby Bauer break points (MIC) are based on achievable antimicrobial concentrations in human plasma and MIC\textsubscript{90} values for human E coli isolates, which provide a reasonable approximation to achievable MIC values in calf plasma and MIC\textsubscript{90} values for bovine E coli isolates. Unfortunately, susceptibility results are not available for at least 48 hours, and very few studies have documented the antimicrobial susceptibility of blood isolates in calves with diarrhea. In a 1997 study of dairy calves in California, the antimicrobial susceptibility of isolates from the blood of calves with severe diarrhea or illness produced the following results—ceftiofur (19/25 = 76% sensitive), potentiated sulfonamides (14/25 = 56% sensitive), gentamicin (12/25 = 48% sensitive), ampicillin (11/25 = 44% sensitive), and tetracycline (3/25 = 12% sensitive)—although there was a clinically significant year-to-year difference in the results of susceptibility testing that might have reflected different antimicrobial administration protocols on the farm.\textsuperscript{16}

**Success of Antimicrobial Therapy**
The 4 critical measures of success of antimicrobial therapy in calf diarrhea are, in decreasing order of importance, (1) mortality rate, (2) growth rate in survivors, (3) severity of diarrhea in survivors, and (4) duration of diarrhea in survivors. Because many of the early studies on antimicrobial treatment in calf diarrhea were uncontrolled, this review of antimicrobial therapy success has been restricted to studies with adequate numbers, random allocation to groups, and inclusion of an appropriate control group.

Success of antimicrobial therapy can vary with the route of administration and whether the antimicrobial is dissolved in milk, oral electrolyte solutions, or water.\textsuperscript{31,32} Oral antimicrobials administered as a bolus or contained in a gelatin capsule are deposited into the rumen and therefore have a different serum concentration-time profile to antimicrobial agents dissolved in milk replacer that are suckled by the calf or administered as an oral drench at the back of the pharynx.\textsuperscript{24,30,31,33} Antimicrobial agents that bypass the rumen are not thought to alter rumen microflora, potentially permitting bacterial recolonization of the small intestine from the rumen.\textsuperscript{30} Finally, when oral antimicrobial agents are administered to calves with diarrhea, the antimicrobial concentration in the small intestinal lumen is lower and the rate of antimicrobial elimination faster than in healthy calves.\textsuperscript{30}

Amoxicillin, chlorotetracycline, neomycin, oxytetracycline, streptomycin, sulfachloropyridazine, sulfamethazine, and tetracycline administered PO are currently labeled in the United States for the treatment of calf diarrhea. No parenteral antimicrobial agents have a label claim in the United States for treating calf diarrhea.

**Success of Oral Antimicrobials in Treating Naturally Acquired Diarrhea.** The studies are summarized in chronological order. A 1954 study in California involved 37 dairy calves with *Salmonella enterica* serotype Bredeney diarrhea.\textsuperscript{34} The mortality rate in calves treated with streptomycin (500 mg IM and PO once, then 750 mg PO q24h for 3 days) was 45% (10/22), which was significantly (\(P = .014\)) higher than the mortality rate (1/15 = 7%) in another group of calves treated with chloramphenicol (500 mg PO q24h for 4 days).\textsuperscript{35} This study was instrumental in promoting the use of oral chloramphenicol to treat calf diarrhea, particularly diarrhea episodes caused by *Salmonella* spp.

A 1959 study in North Carolina involved 63 dairy calves with diarrhea.\textsuperscript{36} Twice daily administration of neomycin sulfate (dose unknown) and nifuraldezone\textsuperscript{e} (dose unknown) PO for 2 days did not alter mortality rate (neomycin, 6/21 = 28%; nifuraldezone, 3/21 = 14%) when compared with nonantimicrobial-treated controls (6/21 = 28%). Among surviving calves, the mean duration of diarrhea tended to be shorter in those treated with neomycin (6.5 days) or nifuraldezone (6.2 days) when compared with untreated control calves (9.7 days). Furazolidone (15 mg/kg PO q24h) also had no effect on mortality when compared with untreated control calves in a 1971 study conducted in Scotland on 24 male Ayrshire calves with diarrhea.\textsuperscript{36}

One of the seminal studies was conducted on 165 beef calves with diarrhea in Saskatchewan, Canada.\textsuperscript{37} Amoxicillin (12 mg/kg PO q12h for 3–5 days) had no effect (\(P = .83\)) on mortality rate (26/83 = 31% in amoxicillin-treated calves; 27/82 = 33% in control calves). Lack of treatment success in this 1975 study was later attributed to a delay in instituting antimicrobial treatment\textsuperscript{38}; antimicrobials were not administered until diarrhea had been present for a number of days. In the same year, a large study was conducted in Europe involving 347 male dairy calves with diarrhea.\textsuperscript{39} Apramycin significantly decreased the mortality rate in calves treated at 20 mg/kg PO q24h for 5 days (mortality 10/118 = 9%, \(P < .001\)) or 40 mg/kg PO q24h (mortality 6/108 = 6%, \(P < .001\)) when compared with untreated controls (mortality 36/121 = 30%). Apramycin administration PO also increased growth rate in survivors. Apramycin is an aminocyclitol antimicrobial with a predominantly gram-negative spectrum of activity.

One hundred fifty-three dairy calves with diarrhea in Arkansas were administered a potentiated sulfonamide or sulfamethazine and neomycin.\textsuperscript{40} Administration of a potentiated sulfonamide (5 mg/kg PO q24h trimethoprim; 25 mg/kg PO q24h sulfadiazine) for 3–5 days had no effect (\(P = .17\)) on the proportion of calves returning to normal fecal consistency (recovery rate 88/101 = 87%) when compared with a combined treatment of 87 mg/kg PO q12h sulfamethazine and 11 mg/kg PO q12h neomycin sulfate (recovery rate 62/78 = 80%) or with an untreated control group (recovery rate 23/31 = 74%, \(P = .097\)).

In a 1998 European study, 174 beef and dairy diarrheic calves <5 days old were randomly assigned to treatment with florourquinolone marbofloxacin\textsuperscript{f} (1 mg/kg PO q24h for 3 days) or amoxicillin-clavulanic acid (12.5 mg/kg PO q12h) as a positive control.\textsuperscript{41} Marbofloxacin treatment produced a significantly (\(P < .05\)) faster return to normal feces (30% by day 1; 73% by day 3) than did amoxicillin-clavulanic acid (10% by day 1; 58% by day 3). *E. coli* K99 was isolated from the feces in 51% of the calves, and the superior response to marbofloxacin was similar whether enterotoxigenic *E. coli* was detected or not detected in the feces of the scouring calves.
Oral administration of chloramphenicol was effective in treating *S. enterica* serotype Bredeney diarrhea, and apramycin and marbofloxac in administered PO were effective in treating undifferentiated diarrhea. Although chloramphenicol and marbofloxac in have demonstrated efficacy, their listing does not condone, support, or suggest that these therapies should be used in the United States.

**Efficacy of Oral Antimicrobials in Treating Experimentally Induced Diarrhea.** Diarrhea was experimentally induced by intraduodenal inoculation with *S. enterica* serotype Dublin in 54 dairy calves aged 1–2 weeks. Treatment began when calves had profuse diarrhea and fever and consisted of administration of 30 mg/kg chloramphenicol, 500 mg furazolidone, 75 mg/kg sulphamethoxydiazole, or 500 mg neomycin sulfate PO q12h. Compared with an untreated control group (16/20 = 80% died), the mortality rate was significantly lower in calves treated with chloramphenicol (1/9 = 11% died, *P* = .0009), furazolidone (2/10 = 20% died, *P* = .0041), and sulphamethoxydiazole (3/9 = 33% died, *P* = .032). The mortality rate in the untreated control group was similar to that obtained in calves treated with neomycin sulfate (3/6 = 50% died, *P* = .29).

Diarrhea was experimentally induced by oral inoculation with *S. enterica* serotype Dublin in 35 dairy calves aged 2–3 days. Daily administration of trimethoprim, sulfadiazine, or both (in 1:5 ratio) was started 24 hours after inoculation, at which time the calves were slightly subdued but otherwise clinically normal, and continued for 5 days. Compared with an untreated control group (5/7 = 71% died), the mortality rate tended to be lower in calves treated with trimethoprim/sulfadiazine boluses (5 mg/kg trimethoprim and 25 mg/kg sulfadiazine; 1/7 = 14% died, *P* = .10). Similar mortality rates were observed in control calves and calves treated with a lower dose of trimethoprim/sulfadiazine (2.5 mg/kg trimethoprim and 12.5 mg/kg sulfadiazine; 4/7 = 57% died, *P* = 1.00), trimethoprim (10 mg/kg; 4/7 = 57% died, *P* = 1.00), or sulfadiazine (50 mg/kg; 6/7 = 86% died, *P* = 1.00).

Enterotoxigenic *E. coli* diarrhea was experimentally induced in 40 calves 5–10 days old, and treatment was administered immediately after diarrhea was detected. The mortality rate was significantly (*P* < .05) lower in calves administered amoxicillin trihydrate in milk replacer (at ~10 mg/kg PO q12h for 4 days; 1/20 = 5%) than in untreated control calves (6/20 = 30%). The duration of diarrhea was significantly (*P* < .01) shorter in calves administered amoxicillin (3.9 ± 0.1 days) than in untreated control calves (5.7 ± 0.2 days).

Diarrhea was experimentally induced in 82 calves by administering an enterotoxigenic strain of *E. coli*, although rotavirus was frequently isolated from calves with diarrhea. Treatment was administered immediately after diarrhea was detected. The mortality rate tended to be lower in calves administered amoxicillin (as amoxicillin trihydrate, 10 mg/kg PO q12h for 2 days; 1/21 = 5%), oral electrolyte solution (1/20 = 5%), or oral electrolyte solution and amoxicillin (0/20 = 0%) than in untreated control calves (4/21 = 19%). The duration of diarrhea was significantly (*P* < .05) shorter in calves administered amoxicillin (3.1 ± 1.9 days), oral electrolyte solution (3.1 ± 1.1 days), or oral electrolyte solution and amoxicillin (2.3 ± 1.5 days) than in untreated control calves (4.6 ± 2.3 days).

In a study of forty-three 1-day-old calves with experimentally induced enterotoxigenic *E. coli* diarrhea, oral administration of cephapirin C, a broad-spectrum β-lactam antimicrobial that is β-lactamase resistant and not absorbed from the intestine, caused a significant (*P* < .0001) decrease in mortality (3/22 = 14%) in treated calves compared with control calves (19/21 = 90% mortality) and greatly decreased fecal *E. coli* bacterial concentrations.

In a related study in thirty-one 1–3-day-old calves with experimentally induced enterotoxigenic *E. coli* diarrhea, oral administration of L-640,876, a broad-spectrum, potent β-lactam antimicrobial, caused a significant (*P* < .01) decrease in mortality (1/9 = 11%) in treated calves compared with control calves (9/11 = 82% mortality) and greatly decreased fecal *E. coli* bacterial concentrations.

In a 1998 study, enterotoxigenic *E. coli* diarrhea was experimentally induced in 30 calves (<1 day old), and calves were randomly assigned to treatment with fluoroquinolone enrofloxacin (5 mg/kg PO q24h for 3 days) or no treatment. Oral administration of enrofloxacin significantly decreased the mortality rate (7/15 = 47% versus 13/15 = 87%, *P* = .020).

Oral administration of chloramphenicol, furazolidone, sulphamethoxydiazole, broad-spectrum β-lactam antimicrobials (amoxicillin, cephapirin C, L-640,876), and enrofloxacin was effective in treating experimentally induced enterotoxigenic *E. coli* or *S. enterica* serotype Dublin diarrhea. Although chloramphenicol, furazolidone, and enrofloxacin have demonstrated efficacy, their listing here does not condone, support, or suggest that these therapies should be used in the United States.

**Efficacy of Parenteral Antimicrobials in Treating Naturally Acquired Diarrhea.** Chloramphenicol (15 mg/kg IM q24h) had no effect on mortality when compared with untreated control calves in a 1971 study in Scotland involving 20 male Ayrshire calves with diarrhea. Administration of chloramphenicol (20 mg/kg IV q12h) combined with nifuraldezone (60 mg/kg initially, then 30 mg/kg PO q12h for 3 days) also had no effect (*P* = .13) on mortality rate (20/89 = 22% in antimicrobial-treated calves; 27/82 = 33% in control calves) in a study involving 171 diarrheic beef calves in Saskatchewan, Canada.

In a 1975 study conducted in Europe involving 181 male dairy calves with diarrhea, injection of apramycin (20 mg/kg q24h, untreated route, for 5 days) significantly (*P* = .030) decreased the mortality rate (5/90 = 6%) compared with untreated controls (14/91 = 15%). Apramycin injection also increased the growth rate in survivors. A study involving 25 male Holstein calves with diarrhea was conducted in the same year in the United States. Ampicillin trihydrate (400 mg/kg IM q24h) combined with nitrofurzone (12 oz) 57 g PO q24h for 5 days improved (*P* < .05) the general appearance (assessed subjectively by appetite, coat condition, morbidity) on day 5 and day 12 when compared with nonantimicrobial-treated control calves.

Twenty diarrheic calves were treated with oral, subcutaneous, and intravenous fluids and trimethoprim/sulfonamide (IM at “the recommended dose” for up to 7 days) or no treatment (controls) in a 1980 study conducted in...
Scotland. No difference in mortality rate was detected between antimicrobial-treated (6/10 = 60%) and control (4/10 = 40%) calves.

Another seminal study was conducted in 1987 at multiple locations in Europe involving 318 diarrheic calves. Calves were randomly assigned to 1 of 3 treatment groups: sulbactam-ampicillin (9.9 mg/kg IM q24h; 10/105 = 10% mortality), ampicillin (6.6 mg/kg IM q24h; 15/107 = 14% mortality), or untreated control (28/106 = 26% mortality). Treatment was instituted immediately on detection of diarrhea. This study indicated a lower mortality rate in calves treated with sulbactam-ampicillin (P = .0014) or ampicillin (P = .024) and provided strong support for the routine parenteral administration of broad-spectrum β-lactam antimicrobials in the treatment of undifferentiated calf diarrhea.

The study also indicated that administration of sulbactam (penicillinic acid sulfone), which is a potent irreversible inhibitor of β-lactamase, increased the treatment efficacy of parenteral ampicillin. Parenteral administration of apramycin or the β-lactam antimicrobial ampicillin was effective in treating naturally acquired diarrhea, and treatment efficacy of ampicillin was increased with β-lactamase inhibition.

**Efficacy of Parenteral Antimicrobials in Treating Experimentally Induced Diarrhea.** A study was conducted in 38 male dairy calves aged 1–2 weeks with experimentally induced enterotoxigenic E coli diarrhea. After diarrhea induction, calves were randomized into 3 treatment groups consisting of danofloxacin, a fluoroquinolone antimicrobial (1.25 mg/kg IM q24h for 3 days), a positive control baquolprim/sulphadimidine (10 mg/kg IM q24h for 3 days), or untreated controls. Although most calves developed only mild diarrhea and did not become severely ill (all calves survived), danofloxacin decreased the time taken to recover to a normal demeanor and prevented development of mild metabolic acidosis. Compared with potentiated sulfonamide–treated calves, danofloxacin increased weight gain.

Diarrhea was experimentally induced by oral inoculation with S enterica serotype Dublin in 58 dairy calves aged 2–3 weeks. Daily administration of trimethoprim/sulfadiazine (in a 1:5 ratio) was started 24 hours after inoculation, at which time the calves were slightly subdued but otherwise clinically normal, and continued for 5 days. Compared with untreated controls (19/22 = 86% died), the mortality rate was significantly lower in calves treated with trimethoprim/sulfadiazine (20 mg/kg sulfadiazine and 4 mg/kg trimethoprim IV; 2/14 = 14% died, P < .0001), trimethoprim/sulfadiazine (20 mg/kg sulfadiazine and 4 mg/kg trimethoprim IM; 1/14 = 7% died, P < .0001), or a lower dose of trimethoprim/sulfadiazine (10 mg/kg sulfadiazine and 2 mg/kg trimethoprim IV; 1/7 = 14% died, P = .0011). Administration of either sulfadiazine or trimethoprim alone was associated with high mortality rates, demonstrating marked synergism of trimethoprim and sulfadiazine in vivo.

Early IV or IM administration of trimethoprim/sulfadiazine was effective in treating experimentally induced S enterica serotype Dublin diarrhea, and danofloxacin was effective in treating experimentally induced mild enterotoxigenic E coli diarrhea. Although danofloxacin has demonstrated efficacy, its listing does not condone, support, or suggest that this therapy should be used in the United States.

### Evidenced-Based Recommendations for Antimicrobial Administration

The current recommendation by some veterinarians that oral or parenteral antimicrobials should not be used for treating calf diarrhea is not supported by a critical evidence-based review of the literature. The arguments used to support a nonantimicrobial treatment approach are that (1) antimicrobials administered PO alter intestinal flora and function and thereby induce diarrhea, which has been documented on more than 1 occasion with chloramphenicol, neomycin, and penicillin; (2) antimicrobials harm the “good” bacteria more than the “bad” bacteria in the small intestine (an undocumented claim in the calf); (3) antimicrobials are not effective (a statement that is clearly not supported by the results of some published peer-reviewed studies); and (4) antimicrobial administration promotes the selection of antimicrobial resistance in enteric bacteria.

Oxytetracycline and sulfachloropyridazine administered parenterally and amoxicillin, chlortetracycline, neomycin, oxytetracycline, streptomycin, sulfachloropyridazine, sulfamethazine, and tetracycline administered PO are currently labeled in the United States for the treatment of calf diarrhea. Of the 8 antimicrobials administered PO, only amoxicillin has been shown to be efficacious in studies that were conducted with appropriate control groups and published in peer-reviewed journals. In general, the 2 parenteral and 8 oral antimicrobials have been labeled by the U.S. Food and Drug Administration for the treatment and aid in the control of bacterial enteritis (scours, colibacillosis) caused by E coli bacteria susceptible to the antimicrobial. Unfortunately, data supporting the efficacy of parenteral oxytetracycline and sulfachloropyridazine and of oral amoxicillin, chlor-tetracycline, neomycin, oxytetracycline, streptomycin, sulfachloropyridazine, sulfamethazine, and tetracycline in treating calves with naturally acquired diarrhea do not appear to have been published in peer-reviewed journals, and the Freedom of Information summary (www.fda.gov/cvm/eoi) does not supply sufficient information for an independent conclusion of efficacy to be made. Chlortetracycline, neomycin, oxytetracycline, and tetracycline were originally approved as safe for use in the 1950s. Subsequently, the National Academy of Sciences/National Research Council reviewed the available data from 1969 to 1971 and concluded that chlortetracycline, neomycin, oxytetracycline, and tetracycline were probably effective for oral treatment of animal diseases when such diseases were caused by pathogenic microorganisms sensitive to the drug (www.fda.gov/cvm/eoi).

Oral amoxicillin has documented efficacy in the treatment of experimentally induced diarrhea, but amoxicillin administered PO was not efficacious in the treatment of naturally acquired diarrhea in beef calves. Extra-label antimicrobial use (excluding prohibited antimicrobials) is therefore justified in treating calf diarrhea because of the apparent lack of published studies documenting clinical efficacy of antimicrobials with a label claim and because the
health of the animal is threatened and suffering or death might result from failure to treat systemically ill calves.

Because the 2 sites of infection in calf diarrhea are the small intestine and blood, administered antimicrobials should have both local (small intestinal) and systemic effects. In addition, the antimicrobial must reach therapeutic concentrations at the site of infection for a long enough period and, ideally, have only a narrow gram-negative spectrum of activity to minimize collateral damage to other enteric bacteria. In general, oral and parenteral administration of broad-spectrum β-lactam and fluoroquinolone antimicrobials have proven efficacy in treating naturally acquired diarrhea; parenteral administration of trimethoprim/sulfadiazine has proven efficacy in treating experimentally induced diarrhea. Because use of fluoroquinolone antimicrobials in an extra-label manner is illegal in the United States and apramycin is an aminocyclitol roquinolone antimicrobial that is poorly absorbed after oral administration is permitted to treat calf diarrhea, oral fluoroquinolones are recommended because of their high oral absorption.

**Administration of Oral Antimicrobials to Treat E coli Overgrowth of the Small Intestine**

In enteric infections, it is desirable that high intestinal luminal antimicrobial concentrations are maintained with some degree of drug penetration through the intestinal wall. Accordingly, in preruminant calves with diarrhea and mild systemic illness (defined as depressed suckling but normal rectal temperature, hydration status, and heart rate), the veterinarian should continue to monitor the calf’s health or administer amoxicillin trihydrate (10 mg/kg PO q12h) or amoxicillin trihydrate-clavulanate potassium (12.5 mg combined drug/kg PO q12h) for at least 3 days; the latter constitutes extra-label drug use. Amoxicillin trihydrate (10 mg/kg PO q12h in milk replacer) was efficacious in decreasing mortality rate and duration of diarrhea in 2 studies in which diarrhea was experimentally induced with enterotoxigenic E coli bacteria. Amoxicillin trihydrate is 30% absorbed from the calf small intestine, with absorption being similar in milk-fed and fasted calves. After administration of amoxicillin trihydrate (7 mg/kg PO in milk replacer), high antimicrobial concentrations are present in the bile and intestinal contents, with lower antimicrobial concentrations in serum, although serum amoxicillin concentration exceeded 0.5 μg/mL for the duration of treatment. Concurrent feeding of milk and amoxicillin does not change the bioavailability of amoxicillin, although it is absorbed faster when dissolved in an oral electrolyte solution than in milk replacer and absorption is slowed during endotoxemia, presumably because of a decrease in the abomasal emptying rate. Amoxicillin trihydrate is preferred to ampicillin trihydrate for oral administration in calves because it is labeled for the treatment of calf diarrhea in the United States and is absorbed to a much greater extent. However, a field study comparing amoxicillin (400 mg PO q12h) and ampicillin (400 mg PO q12h) treatments for diarrhea reported similar proportions of calves with a good to excellent clinical response (49/62 = 79% for amoxicillin bolus, 59/74 = 80% for amoxicillin powder, 47/65 = 72% for ampicillin bolus, P > .30 for all comparisons). The addition of clavulanate potassium to amoxicillin trihydrate is recommended because clavulanate potassium is a potent irreversible inhibitor of β-lactamase, increasing the antimicrobial spectrum of activity.

Oral administration of potentiated sulfonamides is not recommended for treating calf diarrhea because of the lack of efficacy studies. No other antimicrobial administered PO currently available in the United States is likely to be effective in treating calves with diarrhea, even though gentamicin (50 mg/calf PO Q12h) markedly decreased E coli bacterial concentrations in the feces of healthy calves. Despite 1 study that reported gentamicin (40–80 mg q12h for 3 days, route not stated but presumed to be oral) improved stool consistency in calves with experimentally induced E coli diarrhea, administration of gentamicin PO is not recommended because antimicrobial agents administered to calves with diarrhea should have both local and systemic effects and gentamicin administered PO is poorly absorbed. An additional problem with gentamicin is the prolonged withdrawal time for slaughter, even after oral administration.

Fluoroquinolones clearly have proven efficacy in treating calf diarrhea, and a label indication exists in Europe for oral and parenteral enrofloxacin and oral marbofloxacin for the treatment of calf diarrhea. In those countries where their administration is permitted to treat calf diarrhea, oral fluoroquinolones are recommended because of their high oral bioavailability. However, it must be emphasized that extra-label use of the fluoroquinolone class of antimicrobials in food-producing animals in the United States is illegal and obviously not recommended.

In calves with diarrhea and no systemic illness (normal appetite for milk or milk replacer, no fever), the author recommends that the clinician monitor the health of the calf and not administer oral antimicrobials.

**Administration of Parenteral Antimicrobials to Treat E coli Bacteremia**

In calves with diarrhea and moderate to severe systemic illness, the positive predictive value (DP) of clinical tests (sensitivity [Se] = .39, specificity [Sp] = .91) and the positive predictive value (.77) of clinicopathologic tests (Se = .40, Sp = .95) for detecting bacteremia are too low assuming reasonable estimates for the prevalence of bacteremia (30%). Accordingly, it is recommended that clinicians routinely assume 30% of ill calves with diarrhea are bacteremic and that bacteremia constitutes a threat to the life of the calf. Parenteral antimicrobial treatment is required for these calves.

The most logical parenteral treatment is ceftiofur (2.2 mg/kg IM/SC q12h) for at least 3 days. Ceftiofur is the
most appropriate antimicrobial because it is a broad-spectrum β-lactam antimicrobial that is resistant to the action of β-lactamase; the MIC₉₀ for *E coli* is <0.25 μg/mL³⁴; the recommended dosage schedule maintains free plasma β-lactam antimicrobial concentrations at the desired 4 times above the MIC₉₀ value for the duration of treatment in 7-day-old calves; and 30% of the active metabolite of cef-tiofur (desfuroylceftiofur) is excreted into the intestinal tract of cattle,⁶² providing antimicrobial activity in both blood and small intestine. Moreover, cef-tiofur hydrochloride (2 mg/kg IM once and 0.5 mg/kg PO once) decreased the mortality rate and the severity of diarrhea in pigs with experimentally induced enteric colibacillosis, although these pigs were not suspected to be bacteremic.⁶³ The beneficial effects of parenteral cef-tiofur in these pigs was attributed to decreasing intestinal luminal concentration of pathogenic *E coli*.⁶³ Cef-tiofur sodium (<5 mg/kg PO q24h) was also effective in treating mice with experimentally induced enteric colibacillosis.⁶¹ Administration of cef-tiofur to treat bacteremia and diarrhea in calves constitutes extra-label drug use, and cef-tiofur should not be administered to calves to be processed as veal.

Another recommended treatment is parenteral amoxi-cillin trihydrate or ampicillin trihydrate (10 mg/kg IM q12h) for at least 3 days. Although parenteral ampicillin has proven efficacy in treating naturally acquired diarrhea,³⁸ whereas cef-tiofur has unproven efficacy, the broad-spectrum β-lac-tam antimicrobials amoxicillin and ampicillin are theoretically inferior to cef-tiofur because parenterally administered ampicillin and amoxicillin reach lower plasma concentra-tions, require a higher MIC than cef-tiofur, and are not β-lactamase resistant.⁶¹ Amoxicillin or ampicillin should be injected into the neck musculature because this site provides the greatest absorption⁶² and minimizes damage to more valuable areas of the carcass. Amoxicillin and ami-picillin should not be administered subcutaneously because the rate and extent of absorption is reduced relative to intramuscular injection.⁶¹

A 3rd recommended treatment is parenteral potentiated sulphonamides (20 mg/kg sulfadiazine with 5 mg/kg trimethoprim IV or IM, depending on the formulation characteristics, q24h for 5 days). Efficacy of potentiated sulphonamides has only been proven when treatment began before clinical signs of diarrhea were present.⁴³,⁴⁴ It is therefore unknown whether potentiated sulphonamides are efficacious when administered to calves with diarrhea and depression, although it is likely that potentiated sulphonamides are effi-cacious in the treatment of salmonellosis.

Oral administration of potentiated sulphonamides and apramycin is not recommended for the treatment of bacteremia because of poor oral bioavailability. Oxytetracycline or chlorotetracycline also are not recommended for the treat-ment of bacteremia, although tetracyclines might have some efficacy for treating *E coli* bacterial overgrowth of the small intestine. Tetracycline antimicrobials are bound to calcium, and oral bioavailability when administered with milk is 46% for oxytetracycline and 24% for chlorotetracycline.⁶⁵ Schifferli et al⁶⁵ calculated that oxytetracycline would need to be administered at 20 mg/kg PO q12h to achieve the minimal serum concentrations necessary to treat *E coli* bact-eremia (MIC₉₀ = 4 μg/mL).

In the past, gentamicin has been “considered an appro-priate alternative drug for use in calf diarrheas and pneu-monias when other antimicrobial agents are unsatisfactory.”⁴⁶ Parenteral administration of gentamicin and other aminoglycosides (amikacin, kanamycin) cannot currently be recommended as part of the treatment for calf diarrhea because of the lack of published efficacy studies; prolonged slaughter withdrawal times (15–18 months); potential for nephrotoxicity in dehydrated animals; and availability of ceftiofur, amoxicillin, and ampicillin.

A label indication exists in Europe for parenteral enro-floxacain in the treatment of calf diarrhea. In those countries where administration is permitted to treat calves with diarrhea, parenteral fluoroquinolones are recommended because of their broad-spectrum bactericidal activity, particularly against gram-negative bacteria. However, it must be emphasized that extra-label use of the fluoroquinolone class of antimicrobials in food-producing animals in the United States is illegal and obviously not recommended.

Chloramphenicol had proven efficacy in treating calf diarrhea due to *S enterica* serotype Bredeney and Dublin,⁴³,⁴² although its use is now illegal in the United States. The related antimicrobial florfenicol achieves high concentrations in the small intestinal lumen and is 89% absorbed when administered PO to milk-fed calves⁶⁷; however, florfenicol is not the most appropriate antimicrobial for treating calf diarrhea because the MIC₉₀ for *E coli* is very high at 25 μg/mL,⁶⁸ and florfenicol (11 mg/kg PO or 20 mg/kg IM) failed to reach the MIC₉₀ value in plasma, whereas fleroxacin (11–20 mg/kg IV) only exceeded the MIC₉₀ value for <60 minutes.⁶⁵,⁶⁶,⁷⁰

In calves with diarrhea and no systemic illness (normal appetite for milk or milk replacer, no fever), the author recommends that the clinician monitor the health of the calf and not administer parenteral antimicrobials.

---

**Footnotes**

¹ The use of chloramphenicol in food-producing animals in the United States is prohibited by law because of the occurrence of non-dose-related aplastic anemia in 1 in 10,000–50,000 exposed humans.

² The administration of nitrofurazone and furazolidone in food-producing animals in the United States is prohibited by law because of concerns regarding nitrofurantoin-induced mutagenicity and carcinogenicity.

³ Extra-label administration of fluoroquinolones in food-producing animals in the United States is prohibited by law because of concerns regarding facilitating the emergence of bacteria with multiple antimicrobial resistance, particularly pathogenic enteric bacteria in hu-mans.

---

**References**

1. U.S. Department of Agriculture. Part II: Changes in the U.S. Dairy Industry. 1991–1996. Fort Collins, CO: USDA Animal and Plant Inspection Service, NAHMS, Veterinary Services; 1996:17–21.

2. U.S. Department of Agriculture. Part III: Beef cow/calf health and health management. Fort Collins, CO: U.S. Dept of Agriculture Animal and Plant Inspection Service, NAHMS, Veterinary Services; 1994:37.

3. Carpenter CM, Woods G. The distribution of the colon-aerogenes...
group of bacteria in the alimentary tract of calves. Cornell Vet 1924;14:218–225.

4. Smith T, Orcutt ML. The bacteriology of the intestinal tract of young calves with special reference to early diarrhea. J Exp Med 1925;41:89–106.

5. Smith HW. Observations on the etiology of neonatal diarrhoea (scours) in calves. J Pathol Bacteriol 1962;84:147–168.

6. Isaacsen RE, Moon HW, Schneider RA. Distribution and virulence of Escherichia coli in the small intestines of calves with and without diarrhea. Am J Vet Res 1978;39:1750–1755.

7. Youanas YD, Herdt TH. Changes in small intestinal morphology and flora associated with decreased energy digestibility in calves with naturally occurring diarrhea. Am J Vet Res 1987;48:719–725.

8. Morin M, Lariviere S, Lallier R. Pathological and microbiological observations made on spontaneous cases of acute neonatal calf diarrhea. Can J Comp Med 1976;40:228–240.

9. Moon HW, McLurkin AW, Isaacsen RE, et al. Pathogenic relationships of rotavirus, Escherichia coli, and other agents in mixed infections in calves. J Am Vet Med Assoc 1978;173:577–583.

10. Mebus CA, Stair EL, Underdahl NR, et al. Pathology of neonatal calf diarrhea induced by a Reo-like virus. Vet Path 1971;8:490–505.

11. Dubourguier HC, Gouet P, Mandard O, et al. Scanning electron microscopy of abomasum and intestine of gnotoxenic calves infected either with rotavirus, coronavirus or enteropathogenic Escherichia coli or with rotavirus and E. coli. Ann Rech Vet 1978;9:441–451.

12. Tzipori SR, Smith ML, Halpin C, et al. Intestinal changes associated with rotavirus and enterotoxigenic Escherichia coli infection in calves. Vet Microbiol 1983;8:35–43.

13. Fettman MJ, Brooks PA, Jones RL, et al. Antimicrobial alternatives for calf diarrhea: Enteric responses to Escherichia coli, deoxyribonucleic acid, or gallium in neonatal calves. Am J Vet Res 1987;48:569–577.

14. Reisinger RC. Pathogenesis and prevention of infectious diarrhea (scours) of newborn calves. J Am Vet Med Assoc 1965;147:1377–1386.

15. Fecteau G, Van Metre DC, Marie J, et al. Microbiological culture of blood from critically ill neonatal calves. Can Vet J 1973;8:95–100.

16. Lofstedt J, Dohoo IR, Duizer G. Model to predict septicaemia in diarrheic calves. J Vet Int Med 1999;13:81–88.

17. Knodt CB, Ross EB. Penicillin in milk replacements for dairy calves. Proc Soc Exp Biol Med 1953;82:663–665.

18. Shull JJ, Frederick HM. Adverse effect of oral bacterioidal prophylaxis and therapy on incidence of neonatal calf diarrhea. Vet Small Anim Clin 1978;73:924–930.

19. Rollin RC, Mero KN, Kozishek PB, et al. Diarrhea and malabsorption in calves associated with therapeutic doses of antibiotics: Absorptive and clinical changes. Am J Vet Res 1986;47:987–991.

20. Murley WR, Jacobsen NL, Allen RS. The effect of aureomycin supplementation on growth and feed utilization of young dairy calves. J Dairy Sci 1952;35:846–856.

21. Aslan V, Nizamlioglu M, Kalaycicioglu L, et al. Effect of antibiotic treatment of young calves on glucose absorption and some plasma components. Br Vet J 1989;145:170–173.

22. Holland RE, Herdt TH, Refsal KR. Breath hydrogen concentration and small intestinal malabsorption in calves. Am J Vet Res 1986;47:2020–2024.

23. Huffman EM, Clark CH, Olson JD, et al. Serum chloramphenicol concentrations in preruminant calves: A comparison of two formulations dosed orally. J Vet Pharmacol Ther 1981;4:225–231.

24. Smith HW, Crabb WE. The sensitivity to chemotherapeutic agents of a further series of strains of Bacterium coli from cases of white scours: The relationship between sensitivity tests and response to treatment. Vet Rec 1956;68:274–277.

25. Smith HW. Further observations on the effect of chemotherapy on the presence of drug-resistant Bacterium coli in the intestinal tract of calves. Vet Rec 1958;70:575–580.

26. Boyd JW, Baker JR, Leyland A, et al. Neonatal diarrhea in calves. Vet Rec 1974;115:310–313.

27. Glantz PJ, Kradel DC, Seward SA. Escherichia coli and Salmonella newport in calves: Efficacy of prophylactic and therapeutic treatment. Vet Med Small Anim Clin 1974;69:77–82.

28. Bywater RJ, Palmer GH, Wanstanall SA. Discrepancy between antibiotic (amoxicillin) resistance in vitro and efficacy in calf diarrhea. Vet Rec 1978;102:150–151.

29. Smith HW, Crabb WE. The typing of E. coli by bacteriophage, its application to the study of the E. coli population of the intestinal tract of healthy calves and of calves suffering from white scours. J Gen Microbiol 1965;15:556–574.

30. Mylrea PJ. Passage of antibiotics through the digestive tract of normal and scouring calves and their effect upon the bacterial flora. Res Vet Sci 1968;9:5–13.

31. Thompson SMR, Black WD. A study of the influence of the method of oral administration of ampicillin upon plasma drug levels in calves. Can J Comp Med 1978;42:235–259.

32. Palmer GH, Bywater RJ, Stanton A. Absorption in calves of amoxicillin, ampicillin, and oxytetracycline in milk replacer, water, or an oral rehydration formulation. Am J Vet Res 1983;44:68–71.

33. Dabacker P, Debacker M. Comparative study of chloramphenicol absorption in calves after oral, intra-ruminal and intra-abomasal administration. J Vet Pharmacol Ther 1979;2:195–202.

34. Howarth JA, Cordy DR, Bittle J. Salmonella Bredeney infection of calves and prophylaxis with chloramycin and streptomycin. J Am Vet Med Assoc 1954;124:43–46.

35. Osborne JD, Mochrie RD, Batte EG. Microbiological and therapeutic aspects in calf enteritis. J Am Vet Med Assoc 1959;124:173–177.

36. Fisher EW, Fuente GH. Antibiotics and calf diarrhea—The effect of serum immune globulin concentrations. Vet Rec 1971;89:579–582.

37. Radostitis OM, Rhodes CS, Mitchell ME, et al. A clinical evaluation of antimicrobial agents and temporary starvation in the treatment of acute undifferentiated diarrhea in newborn calves. Can Vet J 1975;16:219–227.

38. Grimshaw WTR, Colman PJ, Petrie L. Efficacy of sulbate-ampicillin in the treatment of neonatal calf diarrhea. Vet Rec 1987;121:162–166.

39. Pankhurst JW, Dzur M, Zeri A, et al. The treatment of disease in the young calf with apramycin. Proceedings 20th World Veterinary Congress, Thessaloniki Greece, 1975:1891–1895.

40. Daniels LB, Fineberg D, Cockrill JM, et al. Use of trimethoprim-sulfadiazine in controlling calf scours. Vet Med Small Anim Pract Agri Pract 1977;72:93–95.

41. Thomas E, Gruet R, Davot JL, et al. Field evaluation of efficacy of marbofloxacin bolus in the treatment of naturally occurring diarrhea in the new born calf. XXTh World Buiatrics Congress, 1998:pp 337–339.

42. van der Walt K, Jenkins WL, Botes HJW. The therapeutic control of calf paratyphoid (S. dublin infection). J S Afr Vet Med Assoc 1967;38:425–430.

43. White G, Pieryc DWT, Gibbs HA. Use of a calf salmonellosis model to evaluate the therapeutic properties of trimethoprim and sulfadiazine and their mutual potentiation in vivo. Res Vet Sci 1981;31:27–31.

44. White G, Pieryc DWT, Clamppit RB, et al. Appraisal of the suitability of a disease model of acute salmonellosis in calves for chemotherapeutic studies. Res Vet Sci 1981;31:19–26.

45. Palmer GH, Bywater RJ, Francis ME. Amoxicillin: Distribution and clinical efficacy in calves. Vet Rec 1977;100:487–491.

46. Bywater J. Evaluation of an oral glucose-glycine-electrolyte formulation and amoxicillin for treatment of diarrhea in calves. Am J Vet Res 1977;38:1983–1987.

47. Jacks TM, Schlein KD, Judith FR, et al. Cephamycin C treat-
ment of induced enterotoxigenic colibacillosis (scours) in calves and piglets. Antimicrob Agents Chemother 1980;18:397–402.
48. Jacks TM, Schleim KD, Miller BM, et al. Quaternary heterocyclamino β-lactams. V. L-640,876 treatment of induced enterotoxigenic colibacillosis (scours) in calves and piglets. J Antibi 1983;36:70–75.
49. Navetat H, Rizet C, Biron P, et al. The therapeutic efficacy of Baytril tablets in the treatment of experimental gastroenteritis by Escherichia coli K99+ in calves. XXth World Buiatrics Congress, 1998:391–393.
50. Hamm D, Hicks WJ. A new oral electrolyte in calf scours therapy. Vet Med Small Anim Clin 1975;70:279–282.
51. Buntain BJ, Selman IE. Controlled studies of various treatments for neonatal calf diarrhoea in calves of known immunoglobulin levels. Vet Rec 1980;107:245–248.
52. White DG, Johnson CK, Cracknell V. Comparison of danofloxacin with baquiloprim/sulphadimidine for the treatment of experimentally induced Escherichia coli diarrhoea in calves. Vet Rec 1998;143:273–276.
53. Lassiter CA. Antibiotics as growth stimulants for dairy cattle: A review. J Dairy Sci 1955;38:1102–1138.
54. Ziv G, Bor A, Soback S, et al. Clinical pharmacology of aminocillin in calves. J Vet Pharmacol Ther 1985;8:95–104.
55. Ziv G, Nouws JFM, Groothuis DG, et al. Oral absorption and bioavailability of amoxicillin derivatives in calves. Am J Vet Res 1977;38:1007–1013.
56. Groothuis DG, van Miert ASIPAM, Ziv G, et al. Effects of experimental Escherichia coli endotoxemia on amoxicillin: amoxycillin blood levels after oral and parenteral administration in calves. J Vet Pharmacol Ther 1978;1:81–84.
57. Larkin PJ. The distribution of a 400 mg dose of amoxicillin administered orally to calves. Vet Rec 1972;90:476–478.
58. Keefe TJ. Clinical efficacy of amoxicillin in calves with colibacillosis. Vet Med Small Anim Clin 1977;72(Suppl):783–786.
59. Staples GE. The influence of certain medicants on fecal bacteria of calves. Vet Med Small Anim Clin 1980;75:867–870.
60. Jones EW, Hamm D, Bush L. Calf diarrheaa: A brief resume with observations on treatment and prevention. Bovine Pract 1977;12:48–53.
61. Yancey RJ, Kinney ML, Roberts BJ, et al. Ceftiofur sodium, a broad-spectrum cephalosporin: Evaluation in vitro and in vivo in mice. Am J Vet Res 1987;48:1050–1053.
62. Brown SA, Chester ST, Robb EJ. Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle. J Vet Pharmacol Ther 1996;19:32–38.
63. Yancey RJ, Evans RA, Kratzer D, et al. Efficacy of ceftiofur hydrochloride for treatment of experimentally induced colibacillosis in neonatal swine. Am J Vet Res 1990;51:349–353.
64. Rutgers LJE, van Miert ASIPAM, Nouws JFM, et al. Effect of the injection site on the bioavailability of amoxycillin trihydrate in dairy cows. J Vet Pharmacol Ther 1980;3:125–132.
65. Schifferli D, Galeazzi RL, Nicolet J, et al. Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves. J Vet Pharmacol Ther 1982;5:247–257.
66. Clarke CR, Short CR, Hsu RC, et al. Pharmacokinetics of gentamicin in the calf: Developmental changes. Am J Vet Res 1985;46:2461–2466.
67. Adams PE, Varma KJ, Powers TE, et al. Tissue concentrations and pharmacokinetics of florfenicol in male veal calves given repeated doses. Am J Vet Res 1987;48:1725–1732.
68. Neu HC, Fu KP. In vitro activity of chloramphenicol and thiamphenicol analogs. Antimicrob Agents Chemother 1980;18:311–316.
69. Craene BA, Deprez P, D’Haese E, et al. Pharmacokinetics of florfenicol in cerebrospinal fluid and plasma of calves. Antimicrob Agents Chemother 1997;41:1991–1995.
70. Lobell RD, Varma KJ, Johnson JC, et al. Pharmacokinetics of florfenicol following intravenous and intramuscular doses to cattle. J Vet Pharmacol Therap 1994;17:253–258.